Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inflectra Launch Prep Continues Post-Deadline, Pfizer Says

Executive Summary

The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.

Advertisement

Related Content

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Pfizer Eliminates Roadblock To Remicade Biosimilar Launch
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade
US Supreme Court Asked To Review Timing Of Biosimilar Entry

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel